单细胞追踪揭示黑色素瘤 TIL 治疗过程中肿瘤反应性 T 细胞的可塑性
Single-cell tracking reveals tumor-reactive T cell plasticity during melanoma TIL therapy.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
TIL（肿瘤浸润淋巴细胞）治疗 pMMR 胃肠道肿瘤患者：是现实吗？
英文原题：Treatment of patients with pMMR GI cancers with tumor-infiltrating lymphocytes (TIL): a reality?
查看英文原题
Treatment of patients with pMMR GI cancers with tumor-infiltrating lymphocytes (TIL): a reality?
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
近期发表于《自然·医学》的一项研究显示，采用经新抗原筛选的TIL（肿瘤浸润淋巴细胞）进行过继细胞治疗，可用于难治性转移性胃肠道癌症，并能产生持久应答；与抗PD-1治疗联合时效果尤为明显。尽管肿瘤突变负荷较低，富集的新抗原反应性TIL仍提高了客观缓解率（ORR），凸显肿瘤微环境的作用，并支持进一步开展临床开发。
展开英文摘要原文
A recent study published in Nature Medicine shows that adoptive cell therapy using neoantigen-selected tumor-infiltrating lymphocytes (TIL) is feasible in refractory metastatic gastrointestinal (GI) cancers, showing durable responses, especially when combined with anti-PD-1. Despite low tumor mutational burden (TMB), enriched neoantigen-reactive TIL improved objective response rates (ORR), highlighting the role of the tumor microenvironment and supporting further clinical development.
论文信息
- 作者
- Haanen JB
- 单位
- Division of Medical Oncology, NKI, Amsterdam, Netherlands; Department of Medical Oncology, LUMC, Leiden, Netherlands; Oncology Service, CHUV, Lausanne, Switzerland. Electronic address: j.haanen@nki.nl.Netherlands
- 期刊
- Trends in cancer2025 Jul
- 原文标识
- PubMed 40441967 · DOI 10.1016/j.trecan.2025.05.004